{Reference Type}: Journal Article
{Title}: Atypical Presentations of Pediatric-acquired Thrombotic Thrombocytopenic Purpura.
{Author}: Ziv A;Dardik R;Yacobovich J;Uziel Y;Haviv R;Avishai E;Kenet G;Toren A;Barel O;Barg AA;
{Journal}: J Pediatr Hematol Oncol
{Volume}: 46
{Issue}: 6
{Year}: 2024 Aug 1
{Factor}: 1.17
{DOI}: 10.1097/MPH.0000000000002914
{Abstract}: <B>BACKGROUND: </B>Immune thrombotic thrombocytopenic purpura (iTTP) in children is a rare, severe thrombotic microangiopathy. This condition is characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia due to reduced activity of the von Willebrand factor-cleaving protease ADAMTS13.<BR><B>METHODS: </B>A retrospective case series evaluating data collected from the medical files of 4 children diagnosed with iTTP.<BR><B>RESULTS: </B>The presented case series depicts a variety of iTTP presentations: 1 case of primary iTTP, 1 case induced by Shiga toxin, 1 associated with RAS-associated autoimmune leukoproliferative disease (RALD), and 1 initial manifestation of systemic lupus erythematosus (SLE). Notably, 2 patients recovered without undergoing plasma exchange.<BR><B>CONCLUSIONS: </B>Early ADAMTS13 testing in children with unexplained hemolysis or thrombocytopenia is crucial. The diverse underlying causes, including infections and autoimmune disorders, underscore the complexity of iTTP in the pediatric population. These cases highlight the necessity for personalized treatment approaches that consider each patient's unique clinical situation and potential alternatives or modifications to conventional therapeutic regimens.